期刊文献+

酮洛芬纳米混悬剂的制备 被引量:1

Preparation of Ketoprofen Nanosuspensions
下载PDF
导出
摘要 目的:制备酮洛芬纳米混悬剂,并对处方及制备工艺进行优化.方法:采用沉淀法与高压均质法相结合的方法制备酮洛芬纳米混悬剂,以粒径及其分布为评价指标,采用单因素考察法优化酮洛芬纳米混悬剂的处方及工艺.结果:通过单因素实验考察后得到的最优处方和工艺制备得到的酮洛芬纳米混悬剂,其粒径为109.6 nm,多分散系数为0.297,平均Zeta电位为-21.1 m V.结论:高压均质法制备的酮洛芬纳米混悬剂处方合理,工艺简单. Objective To optimize the formulation and preparation technology of ketoprofen nanosuspensions. Method The ketoprofen nanosuspensions were prepared by precipitation and high pressure homogenization method and the optimized formulation was obtained by the single factor test method with particle size and its distribution as evaluating indexs. Result The particle size, polydispersity index and Zeta potential of the prepared ketoprofen nanosuspensions were 109.6 nm ,0. 297,-21.1 mV respectively. Conclusion The precipitation and high pressure homogenization technology employed to prepare ketoprofen nanosuspensions is feasible. This study provided potential for the new dosage form development of ketoprofen.
机构地区 辽宁大学药学院
出处 《辽宁大学学报(自然科学版)》 CAS 2015年第2期169-173,共5页 Journal of Liaoning University:Natural Sciences Edition
基金 辽宁省教育厅科学技术研究项目(L2014006) 辽宁大学"大学生创新创业训练计划"(X201310140052)
关键词 酮洛芬 纳米混悬剂 高压均质法 沉淀法 ketoprofen nanosuspensions high pressure homogenization precipitation
  • 相关文献

参考文献12

  • 1Crisp M T,Tucker C J,Rogers T L,et al.Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals[J].J Control Release,2007,117(3):351-359.
  • 2De Smet L,Saerens L,De Beer T,et al.Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs[J].Eur J Pharm Biopharm,2014,87(1):107-113.
  • 3De Waard H,Hinrichs W L,Frijlink H W.A novel bottom-up process to produce drug nanocrystals:controlled crystallization during freeze-drying[J].J Control Release,2008,128(2):179-183.
  • 4Deng J,Huang L,Liu F.Understanding the structure and stability of paclitaxel nanocrystals[J].Int J Pharm,2010,390(2):242-249.
  • 5姚中强,于孟学,韩淑玲.非甾体抗炎药[J].北京医学,2005,27(5):295-300. 被引量:37
  • 6佘庆生.非甾体抗炎药的研发近况[J].江苏药学与临床研究,2005,13(5):11-13. 被引量:3
  • 7Vane J R,Botting J K.Selective COX-2 inhibitors:pharmacology,clinical effects and therapeutic potential[D].Springer,2012.
  • 8Gao L,Zhang D R,Chen M H.Drug nanocrystal for the formulation of poorly soluble drugs and its application as a potential drug delivery system[J].J Nanoparticle Research,2008,10(5):845-862.
  • 9Mathew T H,Vanburen C,Kahan B D,et al.A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection[J].J Clin Pharmacol,2006,46(1):76-87.
  • 10Peters K,Leitzke S,Diederichs J E,et al.Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection[J].J Antimicrob Chemother,2000,45(1):77-83.

二级参考文献44

  • 1Jones R. Non-steroid anti-inflammatory drug prescribing:past,present and future.Am J Med, 2001, 110(Suppl 1A) :4 - 7.
  • 2Sneader W.The discovery of aspirin:a reappraisal. BMJ, 2000, 321:1591 - 1594.
  • 3Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971, 231:232 - 235.
  • 4Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol, 1997, 24:15 - 19.
  • 5Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA, 2002, 99:13926 - 13931.
  • 6Baigeut C , Patron C. Selective cyclooxygenase-2 inhibitors, aspirin,and cardiovascular disease. Arthritis & Rheum, 2003, 48 : 12 - 20.
  • 7Smith TJ. Cyclooxygenases as the principal targets for the actions of NSAIDs. Rheum Dis Clin North Am,1998, 24:501.
  • 8Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs. BMJ, 2002, 325:624 - 627.
  • 9DeKosky ST. Similar enzymes, different mechanisms: COX-1 and COX-2 enzymes in neurologic disease. Arch Neurol, 2003, 60:632 -633.
  • 10Davidson JM, Breyer MD. Inflammatory modulation and wound repair. J Invest Dermatol, 2003, 120:11 - 12.

共引文献38

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部